Eupraxia Pharmaceuticals (EPRX) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Eupraxia Pharmaceuticals (NASDAQ: EPRX) recently:

• 11/11/2026 – Eupraxia Pharmaceuticals had its price target raised by HC Wainwright from $11.00 to $16.00. They now have a “buy” rating on the stock.
• 11/9/2026 – Eupraxia Pharmaceuticals is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $14.00 price target on the stock.
• 11/8/2026 – Eupraxia Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/31/2026 – Eupraxia Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 10/20/2026 – Eupraxia Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer.
• 10/17/2026 – Eupraxia Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/15/2026 – Eupraxia Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/8/2026 – Eupraxia Pharmaceuticals had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 10/1/2026 – Eupraxia Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
• 9/24/2026 – Eupraxia Pharmaceuticals was given a new $25.00 price target by Stifel Nicolaus.
• 9/24/2026 – Eupraxia Pharmaceuticals is now covered by Wedbush. They set an “outperform” rating and a $17.00 price target on the stock.

Eupraxia Pharmaceuticals Price Performance

Shares of EPRX traded up $0.34 during mid-day trading on Friday, hitting $8.14. 550,745 shares of the company traded hands, compared to its average volume of 390,511. Eupraxia Pharmaceuticals Inc. has a one year low of $5.63 and a one year high of $9.32. The company has a current ratio of 12.25, a quick ratio of 16.00 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average of $7.63 and a 200 day moving average of $7.25. The stock has a market capitalization of $547.67 million, a price-to-earnings ratio of -7.68 and a beta of 1.04.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.03. As a group, equities analysts expect that Eupraxia Pharmaceuticals Inc. will post -0.90 earnings per share for the current fiscal year.

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.